CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 249 enrolled
Drug / intervention
NAVISTAR® THERMOCOOL® Catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00412607
NCT00412607Phase 4Completed
CompareCT.gov

NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia

Biosense Webster, Inc.·interventional·Posted Dec 18, 2006·Updated Feb 4, 2025

In Brief

A Phase 4 clinical trial evaluating NAVISTAR® THERMOCOOL® Catheter for Ventricular Tachycardia. Completed, enrolled 249 participants.

Detailed Summary

The primary objective is to provide additional corroborative safety and efficacy data for the Navistar ThermoCool catheter for the treatment of subjects with ischemic Ventricular Tachycardia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Tachycardia
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 18, 2006
Enrollment StartJan 1, 2007
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 19.5 years ago

Interventions

NAVISTAR® THERMOCOOL® Catheterdevice

The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease